Taken together, our results demonstrated that DC-5163, a novel inhibitor targeting GAPDH, suppressed aerobic glycolysis and reduced the energy supply of breast cancer cells, thereby leading to the inhibition of proliferation and increase of apoptosis. This evidence concerns the gene GAPDH and breast carcinoma.